Johnson & Johnson JNJ

S&P 500S&P 500

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$3.39 (+1.64%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Johnson & Johnson (JNJ) Business Model and Operations Summary
    Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

    Key Insights

    Johnson & Johnson (JNJ) Stock Information & Key Business Metrics

    • Market Cap

      $459.34 Billion

    • Average Daily Volume

      8,987,152 Shares

    • 52-Week Range

      $140.68-$194.48

    • Price-Earnings Ratio

      19.81

    • Free Cash Flow

      $17.81 Billion

    • Total Outstanding Shares

      2.41 Billion Shares

    • CEO

      Joaquin Duato

    • Total Employees

      139,800

    • Current Dividend

      No dividend

    • IPO Date

      September 25, 1944

    • SIC Description

      Pharmaceutical Preparations

    • Headquarters

      One Johnson & Johnson Plz, New Brunswick, NJ, 08933

    Financial Highlights

    Johnson & Johnson (JNJ) Key Financial Metrics

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    Income Statement

    Balance Sheet

    Historical Stock Splits

    Historical Dividends

    JNJ Articles From Financhle

    Recent analysis, market insights, and in-depth coverage of JNJ from analysts at Financhle
    • Johnson & Johnson's Q2 2025 Earnings: MedTech Surge, Pipeline Powerhouse, and Cash Flow CurveballsJohnson & Johnson's Q2 2025 earnings showcase a 5.8% sales jump to $23.7 billion and raised full-year guidance, fueled by MedTech momentum and innovative pipeline wins in oncology and robotics. Yet, underlying adjusted dips and negative cash flow highlight strategic bets that could redefine JNJ's future in a competitive healthcare landscape.
      FinanchleJuly 16, 2025

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about JNJ from trusted financial sources

    Related Companies

    Publicly traded companies similar to Johnson & Johnson (JNJ)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.

    Play

    The Daily FinanchleSPY Prediction

    Explore

    Live Market OverviewS&P 500 SPYNasdaq 100 QQQRussell 2000 IWMUnusual Options Activity

    Research

    News ArticlesEarnings CalendarIPO Calendar & DirectoryAll Tickers

    Financhle

    Login / Sign UpPro SubscriptionAbout UsCareersTerms & ConditionsPrivacy & Cookies Info

    â“’ 2025 Financhle LLC. All Rights Reserved.